- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
Papers: 8 May 2021 - 14 May 2021
Animal Studies, Pharmacology/Drug Development
2021 May 12
Eur J Pain
Neuropathic pain (NP) after spinal cord injury (SCI) is a disabling condition, without an effective treatment. Hyperexcitability of N-methyl-D-aspartate (NMDA) receptors and oxidative stress have been reported to be associated with pain development. Amantadine, a NMDA receptor antagonist, has been proposed as a potential therapy for NP. However, its use has not been tested for NP after SCI.